New model paves the way for future antibiotics
Uppsala University
image: Matthew Rosenberg in the chemistry lab in Uppsala, where new antibiotic molecules are synthesised.
Credit: Mikael Wallerstedt
A new antibiotic candidate has taken an important step towards becoming a future medicine via the ENABLE-2 platform. Through this platform, European researchers gain access to laboratory tests and expert advice rather than research grants. Professor Anders Karlén at Uppsala University now wants to make the model available to researchers worldwide.
Modern healthcare is dependent on effective antibiotics, and due to the development of resistance, new medicines are needed. At Uppsala University, a unique platform has been established that bridges the gap between academia and industry, the aim being to assist promising projects through the critical phases of early development.
“We work in the early phase to support existing projects in the university setting and make sure they progress towards further development,” says Anders Karlén. “In June 2026, we reached an important milestone when a project at Justus Liebig University Giessen in Germany received a lead declaration.”
The project focuses on developing a new class of antibiotics that targets a protein that Gram-negative bacteria need to build their protective outer membranes. With support from ENABLE-2, the research group has shown that the selected molecule has sufficiently good efficacy against bacteria and sufficiently low toxicity to be considered promising for further investment, which is required for a lead declaration.
Experiments and advice
At present, nine research groups from various universities in Europe are receiving support from the platform to develop new antibiotics. The aim is to identify and validate promising molecules that other actors can move forward with towards clinical trials. To get to this point, the researchers need to develop and refine the molecules and examine their effect in mice.
“After all, going from curing an infection in an animal model to treating patients is a significant step,” says Anders Karlén. “But we have a strong platform with all the tools necessary to help academic groups in Europe make it through the first phase.”
In addition to support for conducting experiments, the platform offers advice from a range of experts linked to ENABLE-2. The platform is based on the experience and expertise built up between 2014 and 2021 when Uppsala University coordinated the EU project ENABLE.
Bringing together expertise and test systems
In ENABLE, researchers succeeded in taking a substance all the way to a phase 1 study in humans. Development of the medicine has continued, now within the GARDP partnership.
“Antibiotics development is like a relay race,” says Anders Karlén. “You take the molecule part of the way and then someone else takes over. As there are very few pharmaceutical companies involved in this field, we need to find other funding models.”
The continuation of the EU project, ENABLE-2, receives government funding via the Swedish Research Council as part of the national research programme on antibiotic resistance. They have continued to receive applications from all over Europe.
“We’re not a funder but rather a platform that supports research,” says Anders Karlén. “And I think this is a better model. It allows us to bring together experience and expertise within a shared infrastructure that can support many projects in parallel. We’re building up stable test systems and a network of knowledgeable people.”
Long road to a new medicine
The early stages of antibiotics development often take place at universities, but the road from a molecule of interest to a new drug that can be tested on patients is long and full of challenges. If a researcher discovers something that has the potential to become an antibiotic, they need either funding to continue research or collaborators in various fields who can assist them.
“You can apply for funding from research councils or research foundations, but they usually fund basic research rather than pharmaceuticals development,” Anders Karlén notes. “This is where we enter the picture as an important player. Without access to experimental studies and the correct expertise, it’s difficult to make progress.”
Wants to expand globally
ENABLE-2 began in 2022 and will receive funding until 2028. At the present time, Anders Karlén is working intensively on securing funding after 2028, while at the same time exploring opportunities for expansion. With more projects, the chances of reaching the end goal – a new, effective antibiotic – increase.
“We want to increase our capacity and take on more projects in parallel, including from researchers outside Europe,” he says. “Antibiotic resistance is, after all, a global problem, and by growing we would be able to work with the most promising projects, regardless of their location.”
Facts: How ENABLE-2 supports research projects
Research groups at universities and research institutes in Europe can apply for support to develop promising molecules into future antibiotics. Rather than receiving research grants, they gain access to laboratory resources and expert advice.
- Selection: An expert committee assesses which projects have the greatest potential for further development.
- Development: Chemists help improve the properties of the molecules.
- Testing: The molecules are examined in the laboratory to see how effective they are against bacteria, how they are absorbed and broken down, and whether they can cause adverse effects.
- Evaluation: The projects are regularly reviewed by the expert committee, which decides whether development should continue.
- Next steps: When a molecule has shown sufficiently promising properties, the project can receive what is known as a lead declaration. After that, other actors can take over.
The research groups retain ownership of their results, and the support is free of charge.
Read more
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.